Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a/2b study of AG-946 in anemia due to lower-risk myelodysplastic syndromes
MOH_2023-01-11_012279Phase 2Not yet recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tebapivat in myelodysplastic syndrome (MDS) and anaemia (5 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Phase 2a proof of concept and Phase 2b efficacy versus placebo and dose response. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
tebapivat
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on MOH_2023-01-11_012279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-11_012279.